X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA JUBILANT LIFE SCIENCES SHASUN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 123.9 26.3 470.6% View Chart
P/BV x 8.5 5.4 157.9% View Chart
Dividend Yield % 0.2 0.3 69.3%  

Financials

 SHASUN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
SHASUN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs94187 50.4%   
Low Rs4665 70.0%   
Sales per share (Unadj.) Rs214.2364.3 58.8%  
Earnings per share (Unadj.) Rs5.36.8 77.9%  
Cash flow per share (Unadj.) Rs15.824.5 64.6%  
Dividends per share (Unadj.) Rs1.003.00 33.3%  
Dividend yield (eoy) %1.42.4 60.1%  
Book value per share (Unadj.) Rs53.3164.9 32.3%  
Shares outstanding (eoy) m56.62159.28 35.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 94.4%   
Avg P/E ratio x13.118.4 71.2%  
P/CF ratio (eoy) x4.45.1 85.9%  
Price / Book Value ratio x1.30.8 171.6%  
Dividend payout %18.743.8 42.8%   
Avg Mkt Cap Rs m3,95820,061 19.7%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m2,16411,052 19.6%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m12,12758,034 20.9%  
Other income Rs m229191 120.3%   
Total revenues Rs m12,35658,224 21.2%   
Gross profit Rs m1,0095,786 17.4%  
Depreciation Rs m5942,812 21.1%   
Interest Rs m4153,237 12.8%   
Profit before tax Rs m230-72 -318.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m-73696 -10.4%   
Profit after tax Rs m3021,090 27.7%  
Gross profit margin %8.310.0 83.5%  
Effective tax rate %-31.7-965.9 3.3%   
Net profit margin %2.51.9 132.6%  
BALANCE SHEET DATA
Current assets Rs m6,88429,280 23.5%   
Current liabilities Rs m8,45638,912 21.7%   
Net working cap to sales %-13.0-16.6 78.1%  
Current ratio x0.80.8 108.2%  
Inventory Days Days6284 73.0%  
Debtors Days Days10851 212.2%  
Net fixed assets Rs m4,97055,712 8.9%   
Share capital Rs m113155 73.3%   
"Free" reserves Rs m2,87520,968 13.7%   
Net worth Rs m3,02026,265 11.5%   
Long term debt Rs m1,81717,169 10.6%   
Total assets Rs m13,34788,606 15.1%  
Interest coverage x1.61.0 158.9%   
Debt to equity ratio x0.60.7 92.1%  
Sales to assets ratio x0.90.7 138.7%   
Return on assets %5.44.9 110.0%  
Return on equity %10.04.2 241.0%  
Return on capital %13.311.6 115.2%  
Exports to sales %46.437.8 122.7%   
Imports to sales %14.216.5 86.4%   
Exports (fob) Rs m5,62221,933 25.6%   
Imports (cif) Rs m1,7289,567 18.1%   
Fx inflow Rs m5,84322,004 26.6%   
Fx outflow Rs m2,17311,749 18.5%   
Net fx Rs m3,66910,255 35.8%   
CASH FLOW
From Operations Rs m3988,026 5.0%  
From Investments Rs m-1,635-1,744 93.7%  
From Financial Activity Rs m1,309-4,447 -29.4%  
Net Cashflow Rs m711,834 3.9%  

Share Holding

Indian Promoters % 39.2 45.6 86.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 3.6 8.7 41.4%  
FIIs % 17.6 21.2 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 21.1 187.7%  
Shareholders   20,750 23,815 87.1%  
Pledged promoter(s) holding % 12.3 15.9 77.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS